1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 29, 18/Jul/2024
  4. Article
Research Open Access
Like 0
Download

SDG goal 3: hepatitis

Abstract

Background

People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection.

Aim

To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain.

Methods

We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors.

Results

Of all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p < 0.001 for all). These downward trends were confirmed by adjusted logistic regression for the entire study population (adjusted odds ratio (aOR): 0.78), PWID (aOR: 0.78), and PWUD non-IDU (aOR: 0.78).

Conclusions

Our study demonstrates a significant reduction in active HCV infection prevalence among PWUD, particularly in PWID, which suggests that efforts in the prevention and treatment of HCV in Madrid, Spain, have had an impact on the control of HCV infection.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.29.2300712
2024-07-18
2024-11-08
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.29.2300712
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/29/eurosurv-29-29-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.29.2300712&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Hepatitis C, 2024. Geneva: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
  2. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394(10207):1451-66.  https://doi.org/10.1016/S0140-6736(19)32320-7  PMID: 31631857 
  3. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415.  https://doi.org/10.1016/S2468-1253(21)00472-6  PMID: 35180382 
  4. Limia Sánchez A, Olmedo Lucerón C. 2º Estudio de Seroprevalencia en España, 2017-2018 [2nd Seroprevalence Study in Spain, 2017-2018]. Rev Esp Salud Publica. 2021;95:e202103059. PMID: 33734212 
  5. Bhattacharya D, Aronsohn A, Price J, Lo Re V, AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023;ciad319.  https://doi.org/10.1093/cid/ciad319  PMID: 37229695 
  6. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135-84.  https://doi.org/10.1016/S2468-1253(18)30270-X  PMID: 30647010 
  7. Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020;73(5):1170-218.  https://doi.org/10.1016/j.jhep.2020.08.018  PMID: 32956768 
  8. Gamkrelidze I, Pawlotsky JM, Lazarus JV, Feld JJ, Zeuzem S, Bao Y, et al. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021;41(3):456-63.  https://doi.org/10.1111/liv.14779  PMID: 33389788 
  9. World Health Organization (WHO). Draft global health sector strategies on viral hepatitis 2016-2021. Geneva: WHO; 2016. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1
  10. Surey J, Menezes D, Francis M, Gibbons J, Sultan B, Miah A, et al. From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J Antimicrob Chemother. 2019;74(Suppl 5):v17-23.  https://doi.org/10.1093/jac/dkz452  PMID: 31782500 
  11. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-81.  https://doi.org/10.2105/AJPH.2017.304132  PMID: 29267061 
  12. Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis. 2017;64(7):860-9.  https://doi.org/10.1093/cid/ciw869  PMID: 28362947 
  13. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797-808.  https://doi.org/10.1016/S1473-3099(15)00485-5  PMID: 26922272 
  14. Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, et al. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy. 2019;72:181-8.  https://doi.org/10.1016/j.drugpo.2019.06.016  PMID: 31253391 
  15. Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150-66.  https://doi.org/10.1111/add.14393  PMID: 30035835 
  16. Ryan P, Valencia J, Cuevas G, Troya J, Ramon C, Rodríguez A, et al. HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. Int J Drug Policy. 2021;92:103134.  https://doi.org/10.1016/j.drugpo.2021.103134  PMID: 33517130 
  17. Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181-92.  https://doi.org/10.1055/s-0038-1666841  PMID: 29986353 
  18. Ryan P, Valencia J, Cuevas G, Torres-Macho J, Troya J, Pueyo Á, et al. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. Int J Drug Policy. 2021;96:103424.  https://doi.org/10.1016/j.drugpo.2021.103424  PMID: 34429222 
  19. Herranz Mochales A, Picchio CA, Nicolàs A, Macià MD, Fernández-Baca MV, Serrano J, et al. Implementing a new HCV model of care for people who use drugs. JHEP Rep Innov Hepatol. 2024;101145. In press.  https://doi.org/10.1016/j.jhepr.2024.101145 
  20. Not A, Saludes V, Gálvez M, Miralpeix A, Bordoy AE, González N, et al. Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program. J Med Virol. 2023;95(2):e28544.  https://doi.org/10.1002/jmv.28544  PMID: 36727653 
  21. Lazarus JV, Wiktor S, Colombo M, Thursz M, EASL International Liver Foundation. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665-6.  https://doi.org/10.1016/j.jhep.2017.06.033  PMID: 28760329 
  22. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545-63.  https://doi.org/10.1111/add.14012  PMID: 28891267 
  23. Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis. 2018;18(2):215-24.  https://doi.org/10.1016/S1473-3099(17)30676-X  PMID: 29153265 
  24. Vázquez-Morón S, Ryan P, Ardizone-Jiménez B, Martín D, Troya J, Cuevas G, et al. Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting. Sci Rep. 2018;8(1):1858.  https://doi.org/10.1038/s41598-018-20312-5  PMID: 29382904 
  25. Grebely J, Dore GJ. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis. 2011;203(5):571-4.  https://doi.org/10.1093/infdis/jiq111  PMID: 21282190 
  26. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-207.  https://doi.org/10.1016/S2214-109X(17)30375-3  PMID: 29074409 
  27. Bruguera M, Forns X. Hepatitis C en España. [Hepatitis C in Spain]. Med Clin (Barc). 2006;127(3):113-7.  https://doi.org/10.1157/13090276  PMID: 16828003 
  28. Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, et al. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. Int J Drug Policy. 2022;105:103706.  https://doi.org/10.1016/j.drugpo.2022.103706  PMID: 35533635 
  29. Kågström E, Lannergård A, El Khosht J, Lörelius P, Månflod J, Strömdahl S. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden. Harm Reduct J. 2023;20(1):77.  https://doi.org/10.1186/s12954-023-00806-w  PMID: 37328868 
  30. Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, et al. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV Med. 2022;23(7):705-16.  https://doi.org/10.1111/hiv.13229  PMID: 35037379 
  31. González-Baeza A, Dolengevich-Segal H, Pérez-Valero I, Cabello A, Téllez MJ, Sanz J, et al. Sexualized drug use (chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX GESIDA 9416 Study. AIDS Patient Care STDS. 2018;32(3):112-8.  https://doi.org/10.1089/apc.2017.0263  PMID: 29620925 
  32. Gonzalez-Serna A, Macias J, Palacios R, Gómez-Ayerbe C, Tellez F, Rivero-Juárez A, et al. Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain. HIV Med. 2021;22(5):379-86.  https://doi.org/10.1111/hiv.13039  PMID: 33369104 
  33. Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e659-72.  https://doi.org/10.1016/S2214-109X(23)00057-8  PMID: 36996857 
  34. de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction. 2013;108(6):1070-81.  https://doi.org/10.1111/add.12125  PMID: 23347124 
  35. Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019;72:129-37.  https://doi.org/10.1016/j.drugpo.2019.03.017  PMID: 30962036 
  36. Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-Schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. Int J Drug Policy. 2022;102:103588.  https://doi.org/10.1016/j.drugpo.2022.103588  PMID: 35101667 
  37. Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut. 2017;66(8):1507-15.  https://doi.org/10.1136/gutjnl-2016-311504  PMID: 27196586 
  38. Palmateer NE, McAuley A, Dillon JF, McDonald S, Yeung A, Smith S, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction. 2021;116(10):2893-907.  https://doi.org/10.1111/add.15459  PMID: 33651446 
  39. Bardsley M, Heinsbroek E, Harris R, Croxford S, Edmundson C, Hope V, et al. The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. J Viral Hepat. 2021;28(10):1452-63.  https://doi.org/10.1111/jvh.13575  PMID: 34270172 
  40. van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, et al. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019. EClinicalMedicine. 2022;56:101810.  https://doi.org/10.1016/j.eclinm.2022.101810  PMID: 36618902 
  41. Valerio H, Alavi M, Silk D, Treloar C, Martinello M, Milat A, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study. Clin Infect Dis. 2021;73(1):e69-78.  https://doi.org/10.1093/cid/ciaa571  PMID: 32421194 
  42. Lazarus JV, Øvrehus A, Demant J, Krohn-Dehli L, Weis N. The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T’N’T HepC). BMJ Open. 2020;10(11):e039724.  https://doi.org/10.1136/bmjopen-2020-039724  PMID: 33168560 
Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Pablo+Ryan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ryan Pablo</a>, <a href="/search?value1=Jorge+Valencia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Valencia Jorge</a>, <a href="/search?value1=Guillermo+Cuevas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cuevas Guillermo</a>, <a href="/search?value1=Rafael+Amigot-Sanchez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amigot-Sanchez Rafael</a>, <a href="/search?value1=Isidoro+Mart%C3%ADnez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez Isidoro</a>, <a href="/search?value1=Jeffrey+V+Lazarus&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lazarus Jeffrey V</a>, <a href="/search?value1=Felipe+P%C3%A9rez-Garc%C3%ADa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pérez-García Felipe</a>, <a href="/search?value1=Salvador+Resino&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Resino Salvador</a></span>. Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(29):pii=2300712. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.29.2300712" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.29.2300712</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 11 Dec 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 24 Apr 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.29.2300712
/content/10.2807/1560-7917.ES.2024.29.29.2300712
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error